HR+/HER2-
PIK3CA
RT-PCR
biomarkers
breast cancer
liquid biopsy
next-generation sequencing
targeted therapy
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2021
2021
Historique:
received:
21
12
2020
accepted:
10
02
2021
entrez:
12
4
2021
pubmed:
13
4
2021
medline:
13
4
2021
Statut:
epublish
Résumé
Despite the significant achievements in the diagnosis and treatment of metastatic breast cancer (MBC), this condition remains substantially an incurable disease. In recent years, several clinical studies have aimed to identify novel molecular targets, therapeutic strategies, and predictive biomarkers to improve the outcome of women with MBC. Overall, ~40% of hormone receptor (HR)
Identifiants
pubmed: 33842357
doi: 10.3389/fonc.2021.644737
pmc: PMC8027489
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
644737Informations de copyright
Copyright © 2021 Fusco, Malapelle, Fassan, Marchiò, Buglioni, Zupo, Criscitiello, Vigneri, Dei Tos, Maiorano and Viale.
Déclaration de conflit d'intérêts
NF has received honoraria for consulting, advisory role, and/or speaker bureau from Merck Sharp & Dohme (MSD), Boehringer Ingelheim, and Novartis. UM received personal fees (for service in the speaker bureau and as an advisor) from Boehringer Ingelheim, AstraZeneca, Roche, MSD, Amgen, Merck, Eli Lilly, Thermofisher, and Diaceutics. MF received honoraria for consulting, advisory role, speaker bureau, and/or research funding from Astellas Pharma, QED Therapeutics, Diaceutics, Tesaro, Roche, Eli Lilly, and Novartis. CM received honoraria for consulting from Roche, Bayer, AstraZeneca, and Daiichi Sankyo. SB received honoraria for consulting/advisory role/speaker bureau from AstraZeneca, Novartis, Bayer, and Diaceutics. SZ received research funding from AstraZeneca. CC received honoraria for consulting/advisory role/speaker bureau from Novartis, Eli-Lilly, Pfizer, and Roche. PV received honoraria from AstraZeneca, BMS, Celgene, Eli-Lilly, GSK, Incyte, MSD, Novartis, Pfizer, and Teva and research funds from Novartis and Pfizer. AD received honoraria for advisory board roles from Bayer, Roche, Merck, PharmaMar, and Novartis Oncology. EM received honoraria for consulting, advisory role, and/or speaker bureau from Novartis, Roche, and Shire. GV received honoraria for consulting, advisory role, speaker bureau, travel, accommodation, expenses, and/or research funding from MSD Oncology, Pfizer, Dako, Roche/Genetech, Astellas Pharma, Novartis, Bayer, Daiichi Sankyo, Menarini, Ventana Medical Systems Dako/Agilent Technologies, Cepheid, and Celgene. The handling editor declared a shared affiliation, though no other collaboration, with one of the authors UM.
Références
Cancer Discov. 2013 Dec;3(12):1345-54
pubmed: 24265156
Front Oncol. 2020 Jun 16;10:864
pubmed: 32612947
Science. 2007 Dec 14;318(5857):1744-8
pubmed: 18079394
Cancer Manag Res. 2020 Jan 30;12:675-686
pubmed: 32099464
Cancer Res. 2015 Dec 15;75(24):5341-54
pubmed: 26627007
Proc Natl Acad Sci U S A. 2007 Mar 27;104(13):5569-74
pubmed: 17376864
Lancet Glob Health. 2020 Aug;8(8):e1027-e1037
pubmed: 32710860
Clin Cancer Res. 2014 Nov 15;20(22):5823-34
pubmed: 25398847
JAMA Oncol. 2019 Sep 1;5(9):1347-1354
pubmed: 30920609
Breast Cancer (Dove Med Press). 2018 Jan 30;10:23-29
pubmed: 29430197
Ann Transl Med. 2020 Jul;8(14):907
pubmed: 32793751
Ann Oncol. 2019 Dec 1;30(Suppl_10):x3-x11
pubmed: 31859348
J Int Fed Clin Chem. 1997 Dec;9(4):162-70
pubmed: 10177225
J Oncol. 2020 Mar 9;2020:9258396
pubmed: 32211045
Cytopathology. 2015 Oct;26(5):271-83
pubmed: 26399861
Ann Oncol. 2020 Mar;31(3):377-386
pubmed: 32067679
Ann Oncol. 2019 Dec;30 Suppl 10:x12-x20
pubmed: 31928690
Nat Rev Cancer. 2015 Jan;15(1):7-24
pubmed: 25533673
Nucleic Acids Res. 2019 Jan 8;47(D1):D941-D947
pubmed: 30371878
N Engl J Med. 2019 May 16;380(20):1929-1940
pubmed: 31091374
J Cell Sci. 2019 Jan 2;132(1):
pubmed: 30602575
Aging (Albany NY). 2020 Jan 24;12(2):1577-1590
pubmed: 31980592
Cancer Cell. 2014 Oct 13;26(4):479-94
pubmed: 25284480
Int J Cancer. 2021 Feb 1;148(3):528-545
pubmed: 32683679
Breast. 2019 Nov;48 Suppl 1:S26-S30
pubmed: 31839155
Breast Cancer Res Treat. 2010 Apr;120(2):461-7
pubmed: 20107891
Nat Commun. 2016 May 10;7:11479
pubmed: 27161491
Genes (Basel). 2020 Jun 28;11(7):
pubmed: 32605290
JCO Precis Oncol. 2017 Jul;2017:
pubmed: 28890946
Nat Rev Cancer. 2002 Jul;2(7):489-501
pubmed: 12094235
Int J Mol Sci. 2019 Jan 25;20(3):
pubmed: 30691046
Breast Cancer Res. 2012 Feb 13;14(1):R28
pubmed: 22330809
J Mol Diagn. 2013 May;15(3):312-8
pubmed: 23541593
Ann Oncol. 2014 Dec;25(12):2357-2362
pubmed: 25231953
Int J Clin Exp Pathol. 2018 Nov 01;11(11):5450-5458
pubmed: 31949629
Proc Natl Acad Sci U S A. 2012 Sep 18;109(38):15259-64
pubmed: 22949682
Clin Cancer Res. 2017 Jan 1;23(1):26-34
pubmed: 27126994
Cell. 2017 Aug 10;170(4):605-635
pubmed: 28802037
Science. 2004 Apr 23;304(5670):554
pubmed: 15016963
Science. 2019 Nov 8;366(6466):714-723
pubmed: 31699932
Clin Cancer Res. 2014 May 15;20(10):2643-2650
pubmed: 24504125
Drugs. 2019 Jul;79(11):1249-1253
pubmed: 31256368
Breast. 2018 Jun;39:131-138
pubmed: 29679849
Front Oncol. 2014 Apr 14;4:64
pubmed: 24782981
Br J Cancer. 2006 Feb 27;94(4):455-9
pubmed: 16449998
Ann Oncol. 2020 Dec;31(12):1623-1649
pubmed: 32979513
Breast Care (Basel). 2019 Aug;14(4):247-255
pubmed: 31558898
Oncol Rep. 2013 Mar;29(3):1043-52
pubmed: 23314198
Lancet Oncol. 2017 Jul;18(7):904-916
pubmed: 28576675
Front Oncol. 2020 Nov 18;10:620574
pubmed: 33312961
Int J Mol Sci. 2020 Sep 03;21(17):
pubmed: 32899139
Gynecol Oncol. 2015 May;137(2):321-8
pubmed: 25701704
Br J Cancer. 2017 Mar 14;116(6):802-810
pubmed: 28170370
Clin Chem. 2006 Apr;52(4):557-8
pubmed: 16595822
Sci Rep. 2020 Jun 26;10(1):10459
pubmed: 32591580
Mol Oncol. 2019 Dec;13(12):2515-2530
pubmed: 31254443
N Engl J Med. 2012 Feb 9;366(6):520-9
pubmed: 22149876
Nat Rev Cancer. 2020 Feb;20(2):74-88
pubmed: 31686003
BMC Clin Pathol. 2015 Nov 18;15:20
pubmed: 26587011
Sci Rep. 2018 Mar 9;8(1):4290
pubmed: 29523855
Nature. 2011 Jul 20;475(7356):348-52
pubmed: 21776081
Pathol Oncol Res. 2019 Jul;25(3):1117-1123
pubmed: 30426328
Drugs Today (Barc). 2020 Jun;56(6):357-363
pubmed: 32525134
Int J Breast Cancer. 2020 Jun 20;2020:3759179
pubmed: 32637176
Breast Cancer Res. 2020 May 13;22(1):45
pubmed: 32404150